予測バイオマーカーの世界市場レポート 2025年

予測バイオマーカーの市場規模は、今後数年間で安定した成長が見込まれます。2029年にはCAGR4.2％で246億7,000万米ドルに成長します。予測期間の成長は、精密医療の採用の増加、予防医療への関心の高まり、医療費の増加、バイオマーカーに基づく診断への投資の増加、バイオバンクや組織保存施設の拡大、世界の健康意識の高まりなどに起因すると考えられます。予測期間における主な動向としては、バイオマーカー分析における人工知能の統合、非侵襲的バイオマーカー検査の開発、バイオマーカーに基づくデジタルヘルスツールの進歩、シングルセルシーケンス技術の進歩、リアルタイムバイオセンシング・モニタリングシステムの開発、データ統合のためのバイオインフォマティクスツールの進歩などが挙げられます。

がんの罹患率の増加は、予測バイオマーカー市場の成長を促進すると予想されます。がんは、制御不能な細胞増殖を特徴とし、身体の他の部位に浸潤・転移する可能性があります。このようながん患者の増加は、人口の高齢化、ライフスタイルの変化、タバコの使用、食生活の乱れ、環境汚染物質などの危険因子にさらされる機会が増えたことが主な原因です。予測バイオマーカーは、特定の治療が有効である可能性の高い患者を特定するのに役立ち、より個別化された効果的な治療を可能にします。例えば、フランスに本部を置く世界保健機関（WHO）のがん研究専門機関である国際がん研究機関（IARC）の報告書によると、2024年4月、2022年の新規がん患者数は約2,000万人、がん関連死亡者数は約1,000万人でした。予測によると、2050年までに新たながん患者数は年間3,500万人に増加し、2022年の水準から77％増加します。その結果、がん患者数の増加が予測バイオマーカー市場を押し上げると予想されます。

予測バイオマーカー市場の主要企業は、バイオマーカー開発を加速させるために、AIを活用したバイオマーカー探索などの技術的進歩を活用するようになってきています。このアプローチは、より個別化された効果的な治療法をより迅速に提供することで、競争優位性を獲得するのに役立ちます。AIを活用したバイオマーカー探索は、大規模で複雑なデータセットの解析を容易にし、従来の手法では見逃してしまうような予測バイオマーカーを発見します。例えば、2024年7月、米国のプレシジョン・イムノロジー企業であるサイファー・メディシン社はPRoBeNet（Predictive Response Biomarkers using Network Medicine）を発表しました。このプラットフォームは、AIとネットワーク生物学を活用することで、複雑な疾患に対する反応予測バイオマーカーの開発を加速させることを目的としています。PRoBeNetは、治療標的タンパク質と疾患特異的分子シグネチャーを統合することにより、治療反応に関連するバイオマーカーを同定します。関節リウマチ、潰瘍性大腸炎、クローン病などの自己免疫疾患で検証されており、他の複雑な疾患や医薬品開発段階にも適用可能です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界予測バイオマーカーPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の予測バイオマーカー市場：成長率分析
• 世界の予測バイオマーカー市場の実績：規模と成長, 2019-2024
• 世界の予測バイオマーカー市場の予測：規模と成長, 2024-2029, 2034F
• 世界予測バイオマーカー総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の予測バイオマーカー市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• がん
• 代謝性疾患
• 心血管疾患
• 免疫疾患
• その他の適応症
• 世界の予測バイオマーカー市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• スクリーニング
• 分析
• 診断
• 予測
• 監視
• 世界の予測バイオマーカー市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 診断センター
• 契約調査機関
• 学術調査機関
• 製薬会社とバイオテクノロジー企業
• その他のエンドユーザー
• 世界の予測バイオマーカー市場がんの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 乳がん
• 肺がん
• 前立腺がん
• 大腸がん
• 卵巣がん
• 白血病とリンパ腫
• 黒色腫
• 膵臓がん
• 腎臓がん
• 頭頸部がん
• 世界の予測バイオマーカー市場代謝性疾患の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 1型および2型糖尿病
• 肥満
• メタボリックシンドローム
• 非アルコール性脂肪性肝疾患（NAFLD）
• 脂質異常症
• インスリン抵抗性
• 世界の予測バイオマーカー市場、心血管疾患の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 動脈硬化症
• 冠動脈疾患
• 心不全
• 心筋梗塞（心臓発作）
• 不整脈
• 高血圧
• 脳卒中
• 末梢動脈疾患
• 世界の予測バイオマーカー市場、免疫疾患のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 自己免疫疾患
• 炎症性腸疾患（IBD）
• 多発性硬化症
• 乾癬
• アレルギー疾患
• 喘息
• 慢性閉塞性肺疾患（COPD）
• 免疫不全疾患
• 世界の予測バイオマーカー市場、その他の適応症のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 神経疾患
• 感染症
• 腎臓疾患
• 変形性関節症
• 遺伝性疾患
• 呼吸器疾患

第7章 地域別・国別分析

• 世界の予測バイオマーカー市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の予測バイオマーカー市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 予測バイオマーカー市場：競合情勢
• 予測バイオマーカー市場：企業プロファイル
  • Johnson & Johnson Services Inc Overview, Products and Services, Strategy and Financial Analysis
  • F Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Merck KGaA
• Siemens Healthcare GmbH
• Agilent Technologies Inc
• PerkinElmer Inc
• Illumina Inc
• Bio-Rad Laboratories Inc
• QIAGEN GmbH
• Almac Group Limited
• ArcherDX Inc
• Luminex Corporation
• Guardant Health Inc
• Meso Scale Diagnostics LLC
• Myriad Genetics Inc
• NanoString Technologies Inc
• Fujirebio Inc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 予測バイオマーカー市場2029：新たな機会を提供する国
• 予測バイオマーカー市場2029：新たな機会を提供するセグメント
• 予測バイオマーカー市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Predictive biomarkers are biological indicators that help forecast an individual's likelihood of developing a disease or their response to a specific treatment. These markers, which can be genetic, proteomic, or molecular, provide valuable insights into disease susceptibility or treatment efficacy. They enable personalized treatment approaches, enhancing the effectiveness of interventions and potentially reducing adverse effects by identifying patients who are most likely to benefit from specific therapies.

The main indication types for predictive biomarkers include cancer, metabolic diseases, cardiovascular disorders, immunological disorders, and others. Predictive biomarkers for cancer, for example, can reveal a person's risk of developing cancer or predict their response to certain treatments. These biomarkers may include genetic mutations, protein levels, or other biological factors indicative of cancer presence or progression. Applications of predictive biomarkers encompass screening, analysis, diagnosis, prediction, and monitoring. End users of these biomarkers include diagnostic centers, contract research organizations, academic research institutes, pharmaceutical and biotech companies, and other relevant entities.

The predictive biomarkers market research report is one of a series of new reports from the business research company that provides predictive biomarkers market statistics, including predictive biomarkers industry global market size, regional shares, competitors with an predictive biomarkers market share, detailed predictive biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the predictive biomarkers industry. This predictive biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The predictive biomarkers market size has grown steadily in recent years. It will grow from $20.05 billion in 2024 to $20.96 billion in 2025 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to increasing research and development investments, expansion of healthcare infrastructure, collaborations between academic institutions and industry, growing incidence of cancer and genetic disorders, and increased use of biomarkers in drug development.

The predictive biomarkers market size is expected to see steady growth in the next few years. It will grow to $24.67 billion in 2029 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to increasing adoption of precision medicine, growing focus on preventive healthcare, rising healthcare expenditure, increased investment in biomarker-based diagnostics, expansion of biobanks and tissue repositories, and a rise in global health awareness. Major trends in the forecast period include integration of artificial intelligence in biomarker analysis, development of non-invasive biomarker testing, advancements in biomarker-based digital health tools, advancement in single-cell sequencing technologies, development of real-time biosensing and monitoring systems, and advancement in bioinformatics tools for data integration.

The increasing incidence of cancer is expected to drive the growth of the predictive biomarkers market. Cancer is characterized by uncontrolled cell growth that can invade and spread to other parts of the body. This rise in cancer cases is largely due to aging populations, lifestyle changes, and greater exposure to risk factors such as tobacco use, poor diets, and environmental pollutants. Predictive biomarkers help identify patients who are likely to benefit from specific treatments, enabling more personalized and effective therapies. For example, a report by the International Agency for Research on Cancer (IARC), a France-based agency of the World Health Organization (WHO) specializing in cancer research, indicated in April 2024 that there were nearly 20 million new cancer cases and about 10 million cancer-related deaths in 2022. Projections suggest that the number of new cancer cases will increase to 35 million annually by 2050, representing a 77% rise from 2022 levels. Consequently, the growing number of cancer cases is expected to boost the predictive biomarkers market.

Major companies in the predictive biomarkers market are increasingly leveraging technological advancements, such as AI-driven biomarker discovery, to accelerate biomarker development. This approach helps them gain a competitive edge by delivering more personalized and effective therapies more quickly. AI-driven biomarker discovery facilitates the analysis of large, complex datasets, uncovering predictive biomarkers that traditional methods might miss. For example, in July 2024, Scipher Medicine, Inc., a US-based precision immunology company, introduced PRoBeNet (Predictive Response Biomarkers using Network Medicine). This platform aims to speed up the development of predictive response biomarkers for complex diseases by using AI and network biology. PRoBeNet identifies biomarkers related to therapy response by integrating therapy-targeted proteins with disease-specific molecular signatures. It has been validated for autoimmune conditions such as rheumatoid arthritis, ulcerative colitis, and Crohn's disease, and is applicable to other complex diseases and drug development stages.

In January 2023, Thermo Fisher Scientific Inc., a US-based biotechnology research company, acquired The Binding Site Group for £2.3 billion. This acquisition aims to strengthen Thermo Fisher's specialty diagnostics segment by incorporating The Binding Site's advanced diagnostic technologies, thereby enhancing oncology testing and patient care for multiple myeloma. The Binding Site Group, a UK-based provider of diagnostic solutions, offers various predictive biomarkers, especially in the fields of hematology and immunology.

Major companies operating in the predictive biomarkers market are Johnson & Johnson Services Inc, F Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthcare GmbH, Agilent Technologies Inc, PerkinElmer Inc, Illumina Inc, Bio-Rad Laboratories Inc, QIAGEN GmbH, Almac Group Limited, ArcherDX Inc, Luminex Corporation, Guardant Health Inc, Meso Scale Diagnostics LLC, Myriad Genetics Inc, NanoString Technologies Inc, Fujirebio Inc, Asuragen Inc, Biognosys AG, Epigenomics AG, OncoCyte Corporation, Biomarker Technologies Inc

North America was the largest region in the predictive biomarkers market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the predictive biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the predictive biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The predictive biomarkers market consists of revenues earned by entities by providing services such as biomarker discovery, validation, and testing, as well as genetic screening, data analysis, and personalized medicine solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The predictive biomarkers market also includes sales of genetic testing kits, molecular diagnostic assays, genomic sequencing tools, and bioinformatics software. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Predictive Biomarkers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on predictive biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for predictive biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The predictive biomarkers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Indication: Cancer; Metabolic Disease; Cardiovascular Disorder; Immunological Disorder; Other Indications
• 2) By Application: Screening; Analysis; Diagnosis; Prediction; Monitoring
• 3) By End User: Diagnostic Centers; Contract Research Organizations; Academic Research Institutes; Pharms And Biotech Companies; Other End Users
• Subsegments:
• 1) By Cancer: Breast Cancer; Lung Cancer; Prostate Cancer; Colorectal Cancer; Ovarian Cancer; Leukemia And Lymphoma; Melanoma; Pancreatic Cancer; Kidney Cancer; Head And Neck Cancer
• 2) By Metabolic Disease: Type 1 and Type 2 Diabetes; Obesity; Metabolic Syndrome; Non-Alcoholic Fatty Liver Disease (NAFLD); Dyslipidemia; Insulin Resistance
• 3) By Cardiovascular Disorder: Atherosclerosis; Coronary Artery Disease; Heart Failure; Myocardial Infarction (Heart Attack); Arrhythmia; Hypertension; Stroke; Peripheral Arterial Disease
• 4) By Immunological Disorder: Autoimmune Diseases; Inflammatory Bowel Disease (IBD); Multiple Sclerosis; Psoriasis; Allergic Diseases; Asthma; Chronic Obstructive Pulmonary Disease (COPD); Immunodeficiency Disorders
• 5) By Other Indications: Neurological Disorders; Infectious Diseases; Renal Diseases; Osteoarthritis; Genetic Disorders; Respiratory Disorders
• Companies Mentioned: Johnson & Johnson Services Inc; F Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc; Abbott Laboratories; Danaher Corporation
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Predictive Biomarkers Market Characteristics

3. Predictive Biomarkers Market Trends And Strategies

4. Predictive Biomarkers Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Predictive Biomarkers Growth Analysis And Strategic Analysis Framework

• 5.1. Global Predictive Biomarkers PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Predictive Biomarkers Market Growth Rate Analysis
• 5.4. Global Predictive Biomarkers Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Predictive Biomarkers Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Predictive Biomarkers Total Addressable Market (TAM)

6. Predictive Biomarkers Market Segmentation

• 6.1. Global Predictive Biomarkers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer
• Metabolic Disease
• Cardiovascular Disorder
• Immunological Disorder
• Other Indications
• 6.2. Global Predictive Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Screening
• Analysis
• Diagnosis
• Prediction
• Monitoring
• 6.3. Global Predictive Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnostic Centers
• Contract Research Organizations
• Academic Research Institutes
• Pharms And Biotech Companies
• Other End Users
• 6.4. Global Predictive Biomarkers Market, Sub-Segmentation Of Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Colorectal Cancer
• Ovarian Cancer
• Leukemia And Lymphoma
• Melanoma
• Pancreatic Cancer
• Kidney Cancer
• Head And Neck Cancer
• 6.5. Global Predictive Biomarkers Market, Sub-Segmentation Of Metabolic Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 1 and Type 2 Diabetes
• Obesity
• Metabolic Syndrome
• Non-Alcoholic Fatty Liver Disease (NAFLD)
• Dyslipidemia
• Insulin Resistance
• 6.6. Global Predictive Biomarkers Market, Sub-Segmentation Of Cardiovascular Disorder, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atherosclerosis
• Coronary Artery Disease
• Heart Failure
• Myocardial Infarction (Heart Attack)
• Arrhythmia
• Hypertension
• Stroke
• Peripheral Arterial Disease
• 6.7. Global Predictive Biomarkers Market, Sub-Segmentation Of Immunological Disorder, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Autoimmune Diseases
• Inflammatory Bowel Disease (IBD)
• Multiple Sclerosis
• Psoriasis
• Allergic Diseases
• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Immunodeficiency Disorders
• 6.8. Global Predictive Biomarkers Market, Sub-Segmentation Of Other Indications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Neurological Disorders
• Infectious Diseases
• Renal Diseases
• Osteoarthritis
• Genetic Disorders
• Respiratory Disorders

7. Predictive Biomarkers Market Regional And Country Analysis

• 7.1. Global Predictive Biomarkers Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Predictive Biomarkers Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Predictive Biomarkers Market

• 8.1. Asia-Pacific Predictive Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Predictive Biomarkers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Predictive Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Predictive Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Predictive Biomarkers Market

• 9.1. China Predictive Biomarkers Market Overview
• 9.2. China Predictive Biomarkers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Predictive Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Predictive Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Predictive Biomarkers Market

• 10.1. India Predictive Biomarkers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Predictive Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Predictive Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Predictive Biomarkers Market

• 11.1. Japan Predictive Biomarkers Market Overview
• 11.2. Japan Predictive Biomarkers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Predictive Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Predictive Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Predictive Biomarkers Market

• 12.1. Australia Predictive Biomarkers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Predictive Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Predictive Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Predictive Biomarkers Market

• 13.1. Indonesia Predictive Biomarkers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Predictive Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Predictive Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Predictive Biomarkers Market

• 14.1. South Korea Predictive Biomarkers Market Overview
• 14.2. South Korea Predictive Biomarkers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Predictive Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Predictive Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Predictive Biomarkers Market

• 15.1. Western Europe Predictive Biomarkers Market Overview
• 15.2. Western Europe Predictive Biomarkers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Predictive Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Predictive Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Predictive Biomarkers Market

• 16.1. UK Predictive Biomarkers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Predictive Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Predictive Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Predictive Biomarkers Market

• 17.1. Germany Predictive Biomarkers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Predictive Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Predictive Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Predictive Biomarkers Market

• 18.1. France Predictive Biomarkers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Predictive Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Predictive Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Predictive Biomarkers Market

• 19.1. Italy Predictive Biomarkers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Predictive Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Predictive Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Predictive Biomarkers Market

• 20.1. Spain Predictive Biomarkers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Predictive Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Predictive Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Predictive Biomarkers Market

• 21.1. Eastern Europe Predictive Biomarkers Market Overview
• 21.2. Eastern Europe Predictive Biomarkers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Predictive Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Predictive Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Predictive Biomarkers Market

• 22.1. Russia Predictive Biomarkers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Predictive Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Predictive Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Predictive Biomarkers Market

• 23.1. North America Predictive Biomarkers Market Overview
• 23.2. North America Predictive Biomarkers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Predictive Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Predictive Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Predictive Biomarkers Market

• 24.1. USA Predictive Biomarkers Market Overview
• 24.2. USA Predictive Biomarkers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Predictive Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Predictive Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Predictive Biomarkers Market

• 25.1. Canada Predictive Biomarkers Market Overview
• 25.2. Canada Predictive Biomarkers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Predictive Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Predictive Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Predictive Biomarkers Market

• 26.1. South America Predictive Biomarkers Market Overview
• 26.2. South America Predictive Biomarkers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Predictive Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Predictive Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Predictive Biomarkers Market

• 27.1. Brazil Predictive Biomarkers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Predictive Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Predictive Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Predictive Biomarkers Market

• 28.1. Middle East Predictive Biomarkers Market Overview
• 28.2. Middle East Predictive Biomarkers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Predictive Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Predictive Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Predictive Biomarkers Market

• 29.1. Africa Predictive Biomarkers Market Overview
• 29.2. Africa Predictive Biomarkers Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Predictive Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Predictive Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Predictive Biomarkers Market Competitive Landscape And Company Profiles

• 30.1. Predictive Biomarkers Market Competitive Landscape
• 30.2. Predictive Biomarkers Market Company Profiles
  • 30.2.1. Johnson & Johnson Services Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Thermo Fisher Scientific Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis

31. Predictive Biomarkers Market Other Major And Innovative Companies

• 31.1. Merck KGaA
• 31.2. Siemens Healthcare GmbH
• 31.3. Agilent Technologies Inc
• 31.4. PerkinElmer Inc
• 31.5. Illumina Inc
• 31.6. Bio-Rad Laboratories Inc
• 31.7. QIAGEN GmbH
• 31.8. Almac Group Limited
• 31.9. ArcherDX Inc
• 31.10. Luminex Corporation
• 31.11. Guardant Health Inc
• 31.12. Meso Scale Diagnostics LLC
• 31.13. Myriad Genetics Inc
• 31.14. NanoString Technologies Inc
• 31.15. Fujirebio Inc

32. Global Predictive Biomarkers Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Predictive Biomarkers Market

34. Recent Developments In The Predictive Biomarkers Market

35. Predictive Biomarkers Market High Potential Countries, Segments and Strategies

• 35.1 Predictive Biomarkers Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Predictive Biomarkers Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Predictive Biomarkers Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250423_r33525_Predictive_Biomarkers_GMR_2025